+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS



The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS



American Journal of Epidemiology 165(10): 1143-1153



Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer. Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry. Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time. Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed. Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers. Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32). Risk of anal cancer increased after 1995 (RH = 2.9). Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4). The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013880094

Download citation: RISBibTeXText

PMID: 17344204

DOI: 10.1093/aje/kwm017


Related references

The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Medicine 7(6): 369-377, 2006

Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. Aids Research and Human Retroviruses 31(5): 514-518, 2015

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. Journal of Clinical Oncology 27(6): 884-890, 2009

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. Journal of Clinical Oncology 21(18): 3447-3453, 2003

Effects of the introduction of highly active antiretroviral therapy (HAART) on the temporal trend of diagnosis of AIDS and AIDS-defining disorders. Le Infezioni in Medicina 8(3): 134-138, 2000

Three to seven concurrent AIDS-defining disorders at first hospitalization of AIDS presenters as an unexpected emerging feature during the era of highly active antiretroviral therapy. Aids 16(17): 2356-2358, 2002

Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. Journal of Acquired Immune Deficiency Syndromes 29(4): 388-395, 2002

Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study. Sexually Transmitted Infections 76(2): 145-B-146, 2000

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clinical Infectious Diseases 48(8): 1138-1151, 2009

AIDS associated cancers in the era of highly active antiretroviral therapy (HAART). Przeglad Epidemiologiczny 61(3): 529-534, 2007

AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 15(4): 439-48; Discussion 448-9, 2001

Malignancies not included among AIDS-defining disorders, in the era of highly active antiretroviral therapy. Recenti Progressi in Medicina 100(12): 547-549, 2009

Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Current Hiv/Aids Reports 5(3): 140-149, 2008

Different pattern of AIDS-defining diseases in persons responding to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 26(4): 394-395, 2001

Aids-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (Haart). Current Hiv Research 5(5): 484-489, 2007